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Iron constitutes the most prevalent nutritional deﬁciency worldwide. In Chile, anaemia epidemiological data is scarce, evaluating
mainly children and women. Our objective was to determine prevalence of anaemia in an inpatient elderly population (≥60 years)
and assess the usefulness of sTfR levels analyzed by other authors as a good predictor in the diﬀerential diagnosis of iron deﬁciency
anaemia and anaemia of chronic disease. Method. We studied medical patients admitted at Hospital of Valdivia (HV), Chile, in
a 2month period. World Health Organization criteria were used for anaemia. Results. 391 patients were hospitalized, average age
62.5 years, 247 elderly and 99 of which had anaemia. Anaemia was normocytic in 88.8%, and we observed: low serum iron in
46.3%, low ferritin 10.1%, high TIBC 2%, low % transferrin saturation (Tsat) 40%, and high sTfR 25%. Conclusions. As a ﬁrst
ﬁgure known in Chile, the prevalence of anaemia in the elderly inpatient was 40.1%. Our ﬁndings encourage us to promote the
implementation of sTfR determination in the clinical setting to analyze the state of erythropoiesis in patients with chronic diseases
wich commonly occurs in elderly.
1.Introduction
Iron (Fe) is an essential metal ion for living beings; although
it is the fourth most abundant mineral in the earth’s crust, it
is the most prevalent nutritional deﬁciency worldwide [1]. It
participates in a variety of vital physiological processes such
as oxygen transportation, energy production in the brain by
cytochrome oxidase, enzymatic cofactor in the synthesis of
neurotransmitters and myelin [2, 3]. The main consequence
of iron deﬁciency is the generation of anaemia which allows
us to estimate its prevalence in a given population indirectly
by red blood cell counting. However, this approach has
the limitation of including other aetiologies. The worldwide
prevalence of iron deﬁciency is approximately 30%, resulting
in close to 2 billion people with anaemia of this cause. In
developing countries, the prevalence of anaemia among
pregnant women and children under two years exceeds 50%
[4, 5]. In Chile, the epidemiological anaemia data is scarce
and sectored, with values ranging from 5.1% in women [6]
up to 36% in infants of low socioeconomic status [7].
Theimpactofirondeﬁciencyoccursnotonlyinthehem-
atopoietic system and is more evident in the early stages of
life aﬀecting preschool children who suﬀer from behavioral
and aﬀective disorders [8], increased infection susceptibility,
and pregnant women having increased risk of preterm de-
livery, low birth weight, and death in the newborn (NB).
Children, especially premature NB children from mothers
with iron deﬁciency, adolescent girls, and women of child-
bearing age [9, 10] represent the most vulnerable population
for this deﬁciency because of their increased demand and/or
physiological loss of Fe.
There is no epidemiological data available of iron de-
ﬁciency in the elderly, but they are expected to have a2 Anemia
higher prevalence of anaemia than in the general population,
since longevity is associated with a variety of physiological
dysfunctions, chronic and inﬂammatory diseases, and occa-
sionally inadequate diet that lower reserves and availability
of Fe. Clinical manifestations of anaemia in the elderly add
to changes in sensory organs, increasing the risk of falls, with
a decline in mobility and loss of autonomy [11] that results
in an increase in health expenses.
When facing a patient with iron deﬁciency anaemia
(IDA), the hematimetric and ferrokinetic classical standards
can be altered by concomitant anaemia of chronic disease
(ACD) secondary to infectious, neoplastic, or inﬂammatory
diseases [12–15]. ACD is the consequence of the production
of pro-inﬂammatory cytokines (IL1, 6, TNFα)[ 15]a n d
some anti-inﬂammatory cytokines (IL-10) which induce the
reticuloendothelial system to store Fe limiting its availability
for erythropoiesis, decrease the half-life of erythrocytes, in-
hibit the production of erythropoietin (Epo) and decrease
the sensitivity of erythroid precursors to Epo [16, 17]. Thus,
ACD by itself results in hypoferremia and hyperferritinemia
thereby complicating etiological diagnosis of patients with
simultaneous IDA. Moreover, normal physiological levels of
serum iron are diﬃcult to establish in a population due to its
circadian rhythm [18], technical limitations of the method,
and frequent indication of ferrous salts [19].
In Fe deﬁciency, the decreased serum iron concentration
leads to an increase in total capacity of iron binding (TIBC)
and a decreased saturation of the iron transporter transferrin
(Tsat).Ferritin(Ferr)andtransferrin(Tf)havethedisadvan-
tage of being acute phase reactants with limited value in the
diﬀerential diagnosis of ACD from IDA [20].
Theaboveconsiderationsjustifyeﬀortstodesignahighly
sensitive and speciﬁc test to detect iron deﬁciency, ideally
before the development of anaemia [21, 22]. Staining of the
iron deposits in bone marrow (BM) remains as the gold
standard, but it is an invasive technique. We assessed the
use of soluble transferrin receptor (sTfR) [23, 24], present
in the serum that can be easily quantiﬁed by conventional
techniques and presents great potential for the distinction
between IDA and ACD [24–26] highly necessary for the
therapeutic treatment in the elderly. Its’ concentration rises
when there is marked lack of intracellular iron as the cell
increases the number of receptors on its membrane [27,
28]. These parameters can eliminate the need of using
BM aspirate to diagnose iron deﬁciency in some cases.
However, it must be remembered that the sTfR commonly
is ubiquitously expressed at low levels. Its expression can be
elevated, in a variety of human cancers [29]. In addition to
i t sr o l ei ni r o nm e t a b o l i s mi th a sb e e ns u g g e s t e dt h a ts T f R
may play a role in cellular signaling and proliferation stimuli
[30].
Our aim was to determine the prevalence of anaemia in a
hospitalized elderly population and quantify the proportion
that corresponds to iron deﬁciency using the ratio sTfR/
logFerr as a gold standard diagnostic parameter, as other
authors [21], in order to assess later its utility in the differ-
ential diagnosis of ACD with IDA in comparison to other
ferrokinetic and hematological classical parameters for use
in the future in elderly patients.
2. Patients andMethods
We studied all the patients who were admitted at the Internal
Medicine Ward at HV, Chile, between October 31 and De-
cember 31, 2008. Prior to informed consent, they were asked
to participate in this research protocol without compromis-
ing medical care for their condition. Identiﬁcation data and
sociodemographicvariableswereasked(age,sex,maritalsta-
tus, health insurance, urban or rural residence, and edu-
cational level), and the cause of their hospitalization was
obtained from the medical history.
We deﬁned as elderly adults those with age ≥60 years.
We assessed the presence of anaemia through the ﬁrst in-
patient complete blood count (CBC) using the World Health
Organization deﬁnition: Hemoglobin (Hb) <13g/dL for
males and 12g/dL for women. Anaemia was considered mi-
crocytic when MCV was ≤80 ﬂ, macrocytic ≥100ﬂ, and
normocytic 81–99 ﬂ. The severity of anaemia was considered
to be severe: (Hb < 7g/dL), moderate (Hb 7–9g/dL) and
mild (Hb 9–11g/dL). Patients with anaemia were further for
analyzed serum iron, serum ferritin, TIBC, Tsat and sTfR
quantiﬁcation. The techniques used in the study and their
normal values according to the manufacturer are shown in
Table 1.
The ratio sTfR/logFerr was calculated in patients with
ferritin <30ng/mL considering the value <1a sc o m p a t i b l e
with ACD, >2 as ACD associated with another etiology
using the ﬂowchart of Weiss and Goodnough [23]. Statistical
analysis was expressed as mean ± SD or range of distribution
if not distributed normally. Statistical calculations were per-
formed with Epidat 3.1.
3. Results
During the study period, 391 patients were hospitalized, out
of which 247 were over 60 years. Details of their socio-
demographic variables are shown in Table 2.I tw a sn o t
possibletosurvey44patientsbecauseoftheirclinicalfeatures
(confusion, dementia, etc.).
The patients hospitalized (n = 391) had an average
hospitalization time of 6.3 days, with an average age of 62.5
years (15–95 years) of which a 63.15% were elderly. The
CBC assessment revealed 99 elderly patients with anaemia
according to the WHO criteria. This allowed us to calculate
a prevalence of anaemia of 40.1% in the elderly inpatient
population. In this population, the mean age was 73.2 years
(60–90); the distribution by sex was59.6% femaleand 40.4%
male. The ﬁrst three causes of hospitalization were in order
of frequency: acute lung infection 12.5%, heart failure 10.2%
and acute coronary syndrome with a 9.9%. Analysis of the
haematological parameters revealed an anaemia distribu-
tion according to morphology of 88.8% normocytic, 9.1%
microcytic and 2% macrocytic; and according to severity:
severe 3% (Hb < 7g/dL), moderate 25% (Hb 7–9g/dL), mild
39% (Hb 9–11g/dL), and of lower intensity 32% (Hb 11 to
12.9g/dL). Ferrokinetic analysis revealed (see Figure 1) that
serum iron was low in 50.5%, normal in 47.5%, and high in
2%; ferritin was low in 10.1%, normal in 52.5%, and high
in 37.4%; TIBC was low in 73.5%, normal in 23.5%, andAnemia 3
Table 1: Techniques for ferrokinetics and haematological parameters and normal values according to manufacturer and iron deﬁciency
criteria used in the study.
Method Manufacturer‘s normal value Iron deﬁciency criteria
Serum iron Iron liquicolor photometric colorimetric
test for iron with lipid clearing
Men 59–148ug/dL
Women 37–145ug/dL
Men < 59ug/dL
Women < 37ug/dL
Total iron-binding capacity (TIBC) TIBC test, iron saturation and aluminum
oxide absorption method, human 250–370ug/dL >370ug/dL
Ferritin (Ferr) Electrochemiluminescence immunoassay.
Roche, Elecsys 2010/modular analytics 30–300ng/mL <30ng/mL
% Transferrin saturation (% Tsat) TIBC test/iron liquicolor, human 20%–45% ref <20%
Soluble transferrin receptor (sTfR) Enzyme-linked quantikine IVD human sTfR
immunoassay 8.7–28.1nmol/L >28,1nmol/L
Ratio sTfR/logFerritin (sTfR/logFerr) 1-2 >2
MCV SYSMEX. XE-alphaN
automated hematology system roche, 80–99 fL ≤80fL
CHCM SYSMEX. XE-alphaN,
automated hematology system roche, 32–36ug/dL ≤32ug/dL
Table 2: Main demographic variables of hospitalized patients,
elderly and those elderly with anaemia.
Total patients
admitted
Elderly
patients
Elderly
patients with
anaemia
Number of cases 391 247 99
Mean Age
(years) 62.5 73 73.2
Residence
Urban 280 180 65
Rural 95 60 27
Not available 16 7 6
Literacy
Yes 288 161 46
No 47 41 20
Not available 56 45 33
Gender(%)
Male 192 118 40
Female 199 129 59
high in 2%, Tsat was low in 40.2%, normal in 44.8%, and
high in 14.6%, and the sTfR quantiﬁcation was low in 1%,
normal in 74.3%, and high in 24.7%. Figure 1, illustrate the
variability of the analyzes ferrokinetics present in the same
group of patients (Elderly anaemic). Example: Serum iron
was low in 50.5% (n = 49 patients) and 14 of them had high
sTfR. Ferritin was low in 10.1% (n = 10) and 6 of them had
high sTfR, %Tsat was low in 40.2% (n = 39) and 10 of them
had high sTfR.
According to sTfR levels, patients were grouped into low
1%, normal 74%, and high 25%. Using the ferritin and
sTfR/logFerr values according to the algorithm suggested by
Weiss [19],weconcludedthattherewere67%ofACD,13.5%
ofIDA,9.3%acombinationofboth,while1.2%couldnotbe
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Figure 1: Schematic representation of the number of patients in
each category according to their ferrokinetic tests results.
categorized. The statistical analysis comparing the sensitivity
and speciﬁcity of the sTfR/LogFerr ratio versus the other fer-
rokinetic parameters (Serum iron, TIBC, Tsat, ferritin, sTfR)
was obtained from receiver operating characteristic (ROC)
curves (Figure 2). The following areas under the curve were
obtained for serum iron 0.2487, Tsat 0.1938 and ferritin
0.1061. sTfR and TIBC areas under curve was better: 0.9609;
0.7538,respectively.Butwhencomparingtheareasunderthe
curve of sTfR and TIBC, any of them is a better diagnostic
support if we do not have other test (e.g.,: Perl’s stain), since
both have asymptotic signiﬁcance less than 0.05. However,
the conﬁdence interval for TIBC test was signiﬁcantly lower
than sTfR, which was a statistically signiﬁcant diﬀerence4 Anemia
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Figure 2:Receiveroperatingcharacteristic(ROC)curvesforSerum
iron, TIBC, Ferritin, % Tsat and sTfR for elderly patients with anae-
mia. sTfR/log Ferr ratio was considered the gold standard.
betweenthetwoareasunderdescribedundertheROCcurves
(χ2 test of homogeneity P = 0.0214).
4. Conclusions
From an epidemiological point of view, the prevalence of
anaemia was 40.1% for elderly hospitalized patients which
is higher than that reported in other age groups in Chile and
was unknown until now [6, 31, 32].
Our study conﬁrms that sTfR quantiﬁcation is a valid
method to analyse the erythropoiesis in several diseases. To
evaluate the clinical usefulness of sTfR in elderly patients for
determining their iron deﬁciency status, receiver operating
characteristic (ROC) curves were used, and the maximum
discrimination cut-oﬀ point was calculated (see Figure 2).
The sTfR was highly superior (sTfR area under ROC curve =
0.9609) to discriminate IDA from ACD in an adult patient
population as compared to the classical ferrokinetics and
haematological parameters. Ferrokinetic studies in the ana-
lyzed population were not useful for evaluating iron reserves
and even were misleading in the diagnosis. A low ferritin
concentration had been described as a good parameter for
diagnosing iron deﬁciency anaemia [33]h o w e v e r ,i to n l y
managed to predict 10% of patients with anaemia of this
type in our study. The low Tsat was consistent with iron
deﬁciency anaemia in 25%, but did not discriminate with
ACD. This is consistent with the fact that transferrin, similar
to ferritin, is an acute phase reactant which is elevated in
inﬂammatory disorders [34], still both are widely used [19]
in clinical practice due to the simpler technique and low cost.
Furthermore, low levels of transferrin or TIBC may be due to
increased degradation rather than decreased synthesis, as a
result of increased protein catabolism secondary to catabolic
or antianabolic proinﬂammatory cytokines [35, 36]. Our
study conﬁrms that the analysis of diﬀerent individual fer-
rokinetic parameters is of little use in patients with con-
comitant systemic diseases, which are especially prevalent in
the elderly; see ROC curves and areas.
In elderly adults requiring hospitalization, ACD was the
primary cause of anaemia constituting over 75% of cases,
while only 10% were due to iron deﬁciency. Folic acid and/
or vitamin B12 deﬁciencies were not analyzed because it
was beyond the scope of this study. Finally, the method of
excellence to evaluate iron deposits remains bone marrow
aspirate analysis with Perls stain constituting in some cases
the only technique for diagnosing iron deﬁciency, however,
this test cannot be performed routinely because it is in-
va-sive, expensive and slow [37, 38]. Our work shows that
quantiﬁcation of sTfR is more sensitive and speciﬁc for
discriminating iron deﬁciency anaemia from anaemia asso-
ciated with inﬂammatory events, consistent with work from
othersauthors[21,23,39,40],andwillbeausefuldiagnostic
tool for the future in our elderly patients. It is also necessary
tonotethatmostofthestudypopulationwasadmittedtothe
hospital primarily for cardiac diseases (29.22%), respiratory
diseases (13.14%), and renal failure (6.17%). The latter is
directlyrelatedtothegenerationofanemiabyalowsecretion
of Epo, which must be considered when making the sTfR test
if a patient with impaired renal function.
ThissTfR/logFerrratiogivesusaninverselinearrelation-
ship of the iron stores state and has the advantage of com-
bining the increase of one parameter (sTfR) and the decline
of another (ferritin) [21, 41]. Our ﬁndings encourage us to
promote the implementation of this determination (sTfR) in
the clinical setting as was previously proposed [24, 26, 42],
andhighinterestfortheelderlyadults.Itisimportanttonote
that this method still requires international standardization
in order to deﬁne normal ranges, which at the present time
limits its routine clinical application [43].
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